This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Gilead Sciences (GILD) Q4 Earnings: What's in the Cards?
by Zacks Equity Research
Gilead Sciences Inc. (GILD ) is scheduled to report fourth-quarter 2016 results on Feb 7, after the market closes.
Key Takeaways from AbbVie's Q4 Call: Humira and the Pipeline
by Arpita Dutt
2017 will be a year of significant R&D investment for AbbVie (ABBV) as well as several late-stage readouts which will give an insight into the company's long term growth prospects.
Biotech Stock Roundup: Synergy Drug Gets FDA Nod, AbbVie, GILD HCV Drugs under EU Review
by Arpita Dutt
There were quite a few updates on the regulatory front this week in the biotech sector including FDA approval for Synergy's (SGYP) drug.
Gilead (GILD) HCV Therapy Application Validated in Europe
by Zacks Equity Research
Gilead Sciences, Inc. (GILD) announced that its MAA for once-daily, single tablet regimen of Sovaldi, velpatasvir 100 mg and voxilaprevir 100 mg (SOF/VEL/VOX) for HCV treatment has been fully validated.
Is Gilead Sciences (GILD) a Great Stock for Value Investors?
by Zacks Equity Research
Let's delve into the value metrics of Gilead Sciences (GILD) and determine whether it is a good value investment right now.
The Zacks Analyst Blog Highlights: Gilead Sciences, Las Vegas Sands, Illinois Tool Works, Pfizer and Lockheed Martin
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Gilead Sciences, Las Vegas Sands, Illinois Tool Works, Pfizer and Lockheed Martin
4 Top Biotech Mutual Funds for 2017
by Zacks Equity Research
Biotechnology shares have welcomed this year in style, marking a striking reversal from last year???s dismal performance
Is the Options Market Predicting a Spike in Gilead Sciences (GILD) Stock?
by Zacks Equity Research
Investors in Gilead Sciences Inc. (GILD) need to pay close attention to the stock based on moves in the options market lately.
Gilead (GILD) HBV Drug Vemlidy Receives European Approval
by Zacks Equity Research
Gilead Sciences (GILD) gained EU approval for Vemlidy for the treatment of chronic HBV infection.
Stock Market Roundup Jan. 11: Health Sector Lower on Trump "Murder" Comment
by Madeleine Johnson
After President-elect Donald Trump said pharmaceutical companies were ???getting away with murder,??? in how much they charge the government for medicines.
The Zacks Analyst Blog Highlights: Gilead Sciences, Pepsi, United Parcel Services, Twitter and Stanley Black & Decker
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Gilead Sciences, Pepsi, United Parcel Services, Twitter and Stanley Black & Decker
Top Research Reports for Pepsi, UPS & Gilead Sciences
by Sheraz Mian
Today's Research Daily features new research reports on 16 major stocks, including Gilead Sciences (GILD), Pepsi (PEP) and United Parcel Services (UPS).
Stock Market News for January 04, 2017
by Zacks Equity Research
Benchmarks finished in the green on the first trading day of 2017 as investors strived to make up for losses suffered during the last few sessions of profit booking
United Therapeutics' PAH Suite Bodes Well, Competition Rife
by Zacks Equity Research
On Dec 29, 2016, we issued an updated report on United Therapeutics Corporation (UTHR).
Biotech Stock Roundup: Conatus Soars on Novartis Deal, Early FDA Nod for Clovis Drug
by Arpita Dutt
Biotech stocks like Conatus (CNAT) and Clovis reported positive developments this week with one company signing a deal and the other getting accelerated FDA approval for its cancer treatment.
Gilead to Pay Merck $2.5B in HCV Patent Dispute, Stock Falls
by Zacks Equity Research
Gilead (GILD) has been ordered to pay $2.5 billion in royalties to Merck (MRK) in the largest patent infringement dispute in the history of the U.S.
Biotech Stock Roundup: Ophthotech Slumps on Fovista Results, Achaogen Skyrockets on Data
by Arpita Dutt
Several companies presented data this week with companies like Achaogen (AKAO) soaring while others like Ophthotech plunged.
The Zacks Analyst Blog Highlights: Gilead Sciences, Medtronic, NVIDIA, Accenture and Simon Property
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Gilead Sciences, Medtronic, NVIDIA, Accenture and Simon Property
Top Research Reports for NVIDIA, Medtronic & Gilead Sciences
by Sheraz Mian
Today's Research Daily features new research reports on 16 major stocks, including Gilead (GILD), Medtronic (MDT) and NVIDIA (NVDA).
The Zacks Analyst Blog Highlights: ExxonMobil, Gilead, Duke Energy, NVIDIA and Monster Beverage
by Zacks Equity Research
The Zacks Analyst Blog Highlights: ExxonMobil, Gilead, Duke Energy, NVIDIA and Monster Beverage
Top Research Reports for Exxon, Duke & Gilead
by Sheraz Mian
Today's Research Daily features new research reports on 16 major stocks, including ExxonMobil (XOM), Gilead (GILD) and Duke Energy (DUK).
The Zacks Analyst Blog Highlights: Allergan, Gilead Sciences, Pfizer, Regeneron Pharmaceuticals and Lion Biotechnologies
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Allergan, Gilead Sciences, Pfizer, Regeneron Pharmaceuticals and Lion Biotechnologies
Pricing Issues Continue to Weigh on the Pharma Sector
by Zacks Equity Research
With generics and biosimilars on the rise, many pharma companies are looking towards new products to pick up the pace and make up for lost sales.
Company News for November 03, 2016
by Zacks Equity Research
Companies In The News are: GILD,AGN,CLX,EL
Gilead (GILD) Misses Q3 Earnings, Reiterates 2016 Guidance
by Madeleine Johnson
Gilead Sciences Inc. (GILD) just released its third quarter fiscal 2016 financial results, posting earnings of $2.70 (accounting for BNRI) and revenues of $7.4 billion.